Patents Assigned to Emory University
-
Publication number: 20130240349Abstract: This disclosure relates to compositions of nanoparticles and methods of their use related thereto such as for solar-to-fuel conversion. In general, the compositions include specific nanostructures that act as photosensitizers can help provide near quantum yield for light driven redox mediator reduction and hydrogen generation. In the presence of a catalyst and redox mediator, compositions described herein can efficiently convert sunlight to hydrogen, providing a versatile approach to solar-to-fuel conversion.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: Emory UniversityInventors: Tianquan Lian, Haiming Zhu
-
Patent number: 8530213Abstract: The present disclosure relates generally to bacterial NADH oxidases and, more particularly, to novel NADH oxidases obtained from Lactobacillus plantarum, and derivatives thereof that demonstrate enzymatic activity for NADH, NADPH, or both NADH and NADPH. The compositions comprising an NADH oxidase obtained from L. plantarum or derivatives thereof include: isolated enzymes; recombinantly produced enzymes and derivatives thereof, as well as catalytically active portions thereof; nucleic acids encoding an NADH oxidase obtained from L. plantarum, derivatives thereof, and portions thereof. The methods of the present invention include isolation of NADH oxidases obtained from L. plantarum, derivatives thereof, and portions thereof, and methods for enzymatic reactions comprising NADH oxidase obtained from L. plantarum, including the production of enantiomer-enriched organic compounds.Type: GrantFiled: December 2, 2010Date of Patent: September 10, 2013Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: Andreas Bommarius, Bettina Bommarius, Jun-Ichiro Hirano, Vaijayanthi Thangavel, Jonathan Taejoo Park
-
Publication number: 20130224310Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.Type: ApplicationFiled: June 5, 2012Publication date: August 29, 2013Applicant: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Patent number: 8518885Abstract: A novel class of peptide ?-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA2-AA1-CO—NH—(CH2)n—R3. Processes for the synthesis of peptidyl ?-ketoamide derivatives. Compositions and methods for inhibiting cysteine proteases, inhibiting calpains, and treating disease caused by cysteine proteases and calpains are provided.Type: GrantFiled: July 16, 2008Date of Patent: August 27, 2013Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: James C. Powers, Jonathan D. Glass, Asli Ovat, Zhaozhao Li
-
Patent number: 8507673Abstract: Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-?]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-?]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.Type: GrantFiled: June 9, 2011Date of Patent: August 13, 2013Assignees: Emory University, Imperial College of Science and TechnologyInventors: Dennis C. Liotta, James P. Snyder, Ashutosh S. Jogalekar, Anthony G. M. Barrett, Matthew John Fuchter, Matthew J. Cook, Sebastian H. B. Kroll
-
Patent number: 8501694Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: GrantFiled: January 23, 2012Date of Patent: August 6, 2013Assignees: Emory University, Baxter International Inc., Baxter Healthcare SAInventors: John S. Lollar, Garrett E. Bergman
-
Patent number: 8486408Abstract: Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject.Type: GrantFiled: October 2, 2009Date of Patent: July 16, 2013Assignee: Emory UniversityInventors: Mohammad S. Hossain, Andrew T. Gewitz, John D. Roback, Edmund K. Waller
-
Patent number: 8455468Abstract: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.Type: GrantFiled: March 10, 2011Date of Patent: June 4, 2013Assignee: Emory UniversityInventors: Stuart W. Hoffman, Arthur L. Kellermann, Donald G Stein, David W. Wright, Douglas W. Lowery-North
-
Patent number: 8435493Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).Type: GrantFiled: November 15, 2010Date of Patent: May 7, 2013Assignee: Emory UniversityInventor: Mark M. Goodman
-
Patent number: 8435923Abstract: Compositions, materials incorporating the compositions, and methods of use thereof, for the protection and/or decontamination of contaminants are disclosed.Type: GrantFiled: March 29, 2007Date of Patent: May 7, 2013Assignee: Emory UniversityInventors: Nelya Okun, Craig Hill, Zhen Luo
-
Patent number: 8435979Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: GrantFiled: December 21, 2009Date of Patent: May 7, 2013Assignees: Emory University, The United States of America as represented by the Dept of Veterans AffairsInventor: Jack L. Arbiser
-
Patent number: 8435972Abstract: Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents.Type: GrantFiled: August 31, 2011Date of Patent: May 7, 2013Assignee: Emory UniversityInventors: Donald G. Stein, Iqbal Sayeed, Fahim Atif
-
Patent number: 8430836Abstract: Various embodiments of the present invention provide a conduit device including an attaching device configured for defining a helical pathway through a tissue wall and complementary ring in cooperation for securing the device within an aperture defined in the tissue wall. Some embodiments of the present invention further provide a system for implanting a conduit device in a tissue wall. More specifically, some embodiments provide a system including a coring device for defining an aperture in a tissue by removing and retaining a tissue core and securely implanting a conduit device therein so as to provide fluid communication between a first and second surface of the tissue wall via the conduit device.Type: GrantFiled: October 11, 2010Date of Patent: April 30, 2013Assignees: Emory University, Georgia Tech Research CorporationInventors: Thomas A. Vassiliades, Ajit Yoganathan, Jorge Hernan Jimenez
-
Patent number: 8426398Abstract: The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor ? (FRa) receptor.Type: GrantFiled: January 8, 2010Date of Patent: April 23, 2013Assignee: Emory UniversityInventors: Harish C. Joshi, Surya N. Vangapandu, Ritu Aneja
-
Patent number: 8420354Abstract: This application provides a process for preparing enantiomerically pure ?-D-dioxolane nucleosides. In particular, a new synthesis of (?)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure ?-D- or ?-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected ?-D- or ?-L-1,3-dioxolane nucleoside.Type: GrantFiled: August 27, 2010Date of Patent: April 16, 2013Assignee: Emory UniversityInventors: Marcos Sznaidman, George R. Painter, Merrick R. Almond, Darryl G. Cleary, Amir Pesyan
-
Patent number: 8420680Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring; R3?R6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(?O); and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.Type: GrantFiled: June 30, 2008Date of Patent: April 16, 2013Assignees: Emory University, NeurOp, Inc.Inventors: Dennis C. Liotta, James P. Snyder, Stephen F. Traynelis, Lawrence Wilson, Cara Mosley, Raymond J. Dingledine, Yesim Altas Tahirovic, Scott J. Myers
-
Patent number: 8394957Abstract: 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.Type: GrantFiled: September 4, 2009Date of Patent: March 12, 2013Assignee: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Patent number: 8394760Abstract: A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a nanospecies, a hydrophobic protection structure including at least one compound selected from a capping ligand, an amphiphilic copolymer, and combinations thereof, wherein the hydrophobic protection structure encapsulates the nanospecies, and at least one histidine-tagged peptide or protein conjugated to the hydrophobic protection structure, wherein the at least one histidine-tagged peptide or protein has at least one binding site.Type: GrantFiled: May 2, 2006Date of Patent: March 12, 2013Assignee: Emory UniversityInventors: Lily Yang, Shuming Nie, Xiaohu Gao, Xiang Hong Peng
-
Publication number: 20130034552Abstract: This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.Type: ApplicationFiled: March 8, 2011Publication date: February 7, 2013Applicants: Baker IDI Heart & Diabetes Institute Holdings Ltd., Emory UniversityInventors: Elliot L. Chaikof, Karlheinz Peter, Danijal Topcic, Carolyn A. Haller, Wookhyun Kim
-
Patent number: D685387Type: GrantFiled: August 8, 2011Date of Patent: July 2, 2013Assignee: Emory UniversityInventors: Serdar Kurtkaya, Iestyn Lewis, Michael George Natchus, James P Snyder